We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
One of the nine relapsing patients developed secondaryAML 18 months after transplant.
2
The response of secondaryAML patients remains inferior.
3
Nearly 60% of the patients had secondaryAML, and about half of patients had adverse risk cytogenetics.
4
Methods: The estimated overall risk of secondaryAML was calculated for the patient population as instances per 1000 patient-years of follow-up.
5
The long-term outcome of such patients with secondaryAML was found to be worse than that of patients with de novo AML.
6
In contrast, an epipodophyllotoxin was used in 12 of 13 previously reported patients who had secondaryAML develop.
7
Conclusions: The authors concluded that the use of epipodophyllotoxins may be associated with an increased risk of having secondaryAML develop in patients with ALL.
8
MK was found in 9.3% of patients and was more frequent in patients with advanced age or secondaryAML.
9
These findings suggest that the cell of origin of secondaryAML and ALL with 11q23 rearrangement is an immature haemopoietic progenitor cell.
10
We detected 2 cases of secondaryAML and 1 case of MDS, 19, 52 and 12 months, respectively, after systemic chemotherapy for breast cancer.